List view / Grid view
From groundbreaking cell and gene therapies to cost-effective drug delivery innovations, Europe is emerging as a hub for life-changing therapies. Explore expert insights and innovative solutions shaping the pharmaceutical industry.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
The medicine becomes the first EU-approved oral treatment for adults who have postpartum depression (PPD).
Winners of this year's awards will be revealed during the opening of CPHI Frankfurt 2025.
The deal with the US biopharma could help address metabolic dysfunction-associated steatohepatitis, one of the most prevalent comorbidities of obesity.
The company’s investment strategy will also encompass AI, digital technology and supply chain infrastructure.
Expanding its collaboration with the US biotech will add novel molecular glue degrader-based medicines to the pharma company’s pipeline.
The ICH Assembly’s decision supports progress in promoting international standards for safety assessment of medicines.
Biotech and research investments from Lilly and AstraZeneca also put on hold as pricing row rumbles on.
The novel approach could enhance quality testing applications in pharmaceutical manufacturing.
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
The regulator’s new principles aim to ease the pathway to regulatory approval for rare disease drug developers in the US.
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
The new Thousand Oaks, California facility will incorporate advanced automation and digital capabilities.
David Weinreich will also serve as its Chief Medical Officer and arrives at the German pharmaceutical group with experience from Amgen, Bayer and Regeneron.
